聚乙二醇洛塞那肽在肾功能不全患者中的药代动力学研究
本研究为单中心、开放标签、平行组、单次给药I期临床试验,纳入轻中度肾功能不全伴或不伴T2DM患者及肾功能正常对照,单次腹部皮下注射PEX168 200 μg后采样至720小时。结果显示中度肾功能不全组Vz/F和CL/F较低,t1/2延长至163小时,AUC0-inf分别增加13%和100.7%,总体耐受性良好,中度肾功能不全可能需调整剂量。
要点
- 中度肾功能不全患者PEX168清除减慢,t1/2延长至163小时。
- 轻度和中度肾功能不全患者AUC0-inf分别增加13%和100.7%。
- 单次200 μg PEX168在肾功能不全患者中总体耐受性良好。
核心结论
- 单次200 μg PEX168在肾功能不全患者中总体耐受性良好。
- 中度肾功能不全患者PEX168体内清除率慢于轻度肾功能不全和肾功能正常者,可能需要调整剂量。
研究设计与样本
- 单中心、开放标签、平行组、单次给药I期临床试验,纳入轻中度肾功能不全伴或不伴T2DM患者,以及年龄、性别和BMI匹配的肾功能正常对照。
主要发现
- 中度肾功能不全组Vz/F和CL/F低于其他组。
- 中度肾功能不全组平均t1/2为163小时,长于轻度肾功能不全组(117小时)和肾功能正常组(121小时)。
- 轻度和中度肾功能不全患者AUC0-inf分别增加13%和100.7%。
- 大多数不良事件为轻度胃肠道反应,仅观察到1例严重不良事件。
临床怎么用
- 中度肾功能不全患者使用PEX168时需关注清除减慢和暴露增加,可能需调整剂量。
- 用药期间应监测胃肠道不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Type 2 diabetes mellitus (T2DM) is commonly complicated by renal impairment. Polyethylene glycol loxenatide (PEX168) is a novel long-acting glucagon-like peptide-1 receptor agonist for T2DM. PEX168 pharmacokinetics was studied to identify requirements for dose-modification in T2DM complicated by renal impairment. METHODS: This was a single-centre, open-labelled, parallel-group, single-dose, phase I clinical trial of patients with mild and moderate renal impairment, and with or without T2DM. Age-, sex- and body mass index-matched subjects with normal renal function, and with or without T2DM were recruited as controls. Subjects received a single abdominal subcutaneous injection of PEX168 200 μg. Pharmacokinetic samples were taken at 0, 24, 48, 72, 96, 120, 144, 216, 312, 480, 648 and 720 hours. RESULTS: Twenty-three patients were included in the pharmacokinetics analysis. Vz/F and CL/F were lower in the moderate impairment group than in the other groups. The mean t1/2 (163 hours) in the moderate impairment group was prolonged compared to the mild impairment (117 hours) and normal (121 hours) groups. AUC0-inf increased by 13 and 100.7% in patients with mild and moderate renal impairment, respectively. Most adverse events were mild gastrointestinal disorders, with only 1 serious adverse event observed. CONCLUSION: A single dose of 200 μg of PEX168 was in general well tolerated in patients with renal impairment. The in vivo clearance rate of PEX168 in patients with moderate renal impairment is slower than in patients with mild renal impairment and normal renal function and dose adjustment might be required (ClinicalTrials.org #NCT02467790).
引用
- Wang J, Huang J, Li W, et al. Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study. Br J Clin Pharmacol. 2019. PMID: 31396983. doi:10.1111/bcp.14091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。